Regeneron Pharmaceuticals Inc. sell dimontalban
Start price
20.04.20
/
50%
€528.00
Target price
23.08.20
€290.00
Performance (%)
-1.52%
End price
23.08.20
€520.00
Summary
This prediction ended on 23.08.20 with a price of €520.00. With a performance of -1.52%, the SELL prediction for Regeneron Pharmaceuticals Inc. by dimontalban was down slightly. dimontalban has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -0.340% | -0.340% | 22.275% | -13.579% |
| iShares Core DAX® | 2,99 % | 3,22 % | 4,27 % | 53,70 % |
| iShares Nasdaq 100 | -1,58 % | -3,17 % | 24,75 % | 76,70 % |
| iShares Nikkei 225® | -2,25 % | -9,92 % | 43,52 % | 60,79 % |
| iShares S&P 500 | -0,01 % | 1,64 % | 20,97 % | 62,81 % |
Comments by dimontalban for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Sell mit Kursziel 290,0